We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $111M
1-Year Est. Return 74.4%
This Fund
S&P 500
This Quarter Est. Return
-3.39%
1 Year Est. Return
-74.4%
3 Year Est. Return
-95.55%
5 Year Est. Return
-99.44%
10 Year Est. Return
-99.5%
AUM
$2.6B
AUM Growth
+$272M
Cap. Flow
+$580M
Cap. Flow %
22.28%
Top 10 Hldgs %
59.11%
Holding
341
New
89
Increased
83
Reduced
62
Closed
85

Top Buys

Rank Stock Value
1
ACHC icon
Acadia Healthcare
ACHC
+$32.4M
2
AZN icon
AstraZeneca
AZN
+$11.6M
3
GEVA
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
+$10.4M
4
QRHC icon
Quest Resource Holding
QRHC
+$8.96M
5
MBOT icon
Microbot Medical
MBOT
+$7.86M

Top Sells

Rank Stock Value
1
WY icon
Weyerhaeuser
WY
+$64.6M
2
TEVA icon
Teva Pharmaceuticals
TEVA
+$53.7M
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$16.1M
4
ACAD icon
Acadia Pharmaceuticals
ACAD
+$13.3M
5
OPK icon
Opko Health
OPK
+$10.5M

Sector Composition

Rank Sector Weight
1 Miscellaneous 92.32%
2 Healthcare 6.56%
3 Energy 0.47%
4 Consumer Discretionary 0.36%
5 Industrials 0.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TVTX icon
126
CALL
Travere Therapeutics
TVTX
$5.81B
$1.54M 0.06%
1,710
+40
+2% +$471
HRTX icon
127
Heron Therapeutics
HRTX
$59.3M
$1.54M 0.06%
185,000
+49,719
+37% +$463K
GEVO icon
128
Gevo
GEVO
$388M
$1.52M 0.06%
741
+648
+697% +$2.16M
OPK icon
129
PUT
Opko Health
OPK
$1.16B
$1.49M 0.06%
1,750
-24,511
-93% -$215K
FOMX
130
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$1.48M 0.06%
+271,200
New +$1.56M
ARWR icon
131
PUT
Arrowhead Research
ARWR
$10.3B
$1.48M 0.06%
1,000
-1,989
-67% -$27.2K
IONS icon
132
CALL
Ionis Pharmaceuticals
IONS
$7.83B
$1.48M 0.06%
+380
New +$13.5K
ITP icon
133
IT Tech Packaging
ITP
$2.68M
$1.43M 0.05%
+103,321
New +$2.04M
CASI
134
DELISTED
CASI Pharmaceuticals
CASI
$1.41M 0.05%
+78,849
New +$1.4M
NPSP
135
PUT
DELISTED
NPS PHARMACEUTICALS INC
NPSP
$1.34M 0.05%
514
-801
-61% -$23K
INFI
136
CALL
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$1.33M 0.05%
+988
New +$11.8K
ARIA
137
PUT
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$1.32M 0.05%
2,437
+541
+29% +$3.16K
ICPT
138
CALL
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$1.3M 0.05%
55
-13
-19% -$3.31K
XOMA
139
CALL
DELISTED
Xoma
XOMA
$1.3M 0.05%
155
+126
+434% +$10.7K
NPSP
140
CALL
DELISTED
NPS PHARMACEUTICALS INC
NPSP
$1.3M 0.05%
+500
New +$14.4K
CEMP
141
CALL
DELISTED
Cempra, Inc.
CEMP
$1.25M 0.05%
1,138
+888
+355% +$8.74K
ARIA
142
CALL
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$1.23M 0.05%
2,272
+2,013
+777% +$11.8K
SKBI
143
DELISTED
SKYSTAR BIO-PHARMACEUTICAL CO COM PAR $.001 (NV)
SKBI
$1.21M 0.05%
+289,110
New +$1.57M
CEMP
144
PUT
DELISTED
Cempra, Inc.
CEMP
$1.17M 0.04%
+1,066
New +$10.5K
ARNA
145
DELISTED
Arena Pharmaceuticals Inc
ARNA
$1.15M 0.04%
27,478
+15,696
+133% +$701K
TBRA
146
DELISTED
Tobira Therapeutics, Inc. Common Stock
TBRA
$1.14M 0.04%
112,394
+97,838
+672% +$1.93M
ARIA
147
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$1.09M 0.04%
202,445
+75,561
+60% +$441K
CRDC
148
DELISTED
CARDICA INC COM NEW (DE)
CRDC
$1.09M 0.04%
+101,914
New +$1.16M
RPRX
149
CALL
DELISTED
Repros Therapeutics Inc.
RPRX
$1.08M 0.04%
+1,087
New +$16.1K
ARNA
150
CALL
DELISTED
Arena Pharmaceuticals Inc
ARNA
$966K 0.04%
231
+200
+645% +$8.93K
4 5
6
7 8

Similar funds

IWA
Independent Wealth Advisors Cary, North Carolina $111M AUM
BFA
Ballast Financial Advisors West Chester, Pennsylvania $110M AUM
WPWM
Western Pacific Wealth Management Lake Forest, Illinois $111M AUM 26.64% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $111M AUM 205.39% 1-Year Est. Return
ZS
Zenith Solutions Philadelphia, Pennsylvania $110M AUM
KC
Karras Company Roy, Utah $110M AUM
FI
FinArc Investments Norwood, Massachusetts $110M AUM
CIM
Catalyst Investment Management Windham, New Hampshire $110M AUM

Sabby Management's Q3 2014 Portfolio in Review

As of Q3 2014, Sabby Management held 341 positions worth $2.6B, up 12% from $2.33B the previous quarter. Its ten largest holdings account for 59% of the portfolio.

Sabby Management deployed $580M of net new capital in Q3 2014, opening 89 new positions and adding to 83 existing holdings. Its largest new stake was Acadia Healthcare: 663,324 shares worth $16.4M.

By sector, the portfolio is most concentrated in Miscellaneous at 92% of assets, up from 87% a quarter earlier, followed by Healthcare and Energy.

On the sell side, the largest reduction was SALIX PHARMACEUTICALS LTD DEL, an estimated $6.87M trimmed.

  • Sabby Management's largest Q3 2014 buy was Acadia Healthcare: 663,324 shares worth $16.4M.
  • Sabby Management added most to AstraZeneca in Q3 2014, an estimated $11.6M increase.
  • Sabby Management's biggest Q3 2014 reduction was SALIX PHARMACEUTICALS LTD DEL, cutting an estimated $6.87M.
  • Sabby Management fully exited Weyerhaeuser in Q3 2014, selling an estimated $64.6M.
  • Sabby Management's ten largest holdings make up 59% of its $2.6B portfolio in Q3 2014.
  • Sabby Management opened 89 new positions and closed 85 in Q3 2014.
  • Sabby Management's portfolio value rose 12% quarter-over-quarter to $2.6B.

Based on Sabby Management's 13F filing for Q3 2014, filed 14 Nov 2014.